NanoViricides (NYSEMKT:NNVC) will present an update on the COVID-19 drug development at the LD 500 investor conference on September 3rd at 11:20 AM EDT.
The Company has completed Chemistry, Manufacture, and Controls studies that would be required for an IND application to the FDA.
NNVC is currently conducting studies to finalize its clinical candidate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.